Trial Profile
A trial to map acute global metabolic effects of esketamine or ketamine drugs in treatment-refractory major depressive disorder patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2016
Price :
$35
*
At a glance
- Drugs Esketamine (Primary) ; Ketamine (Primary)
- Indications Major depressive disorder
- Focus Pharmacodynamics
- 19 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics